Abstract

Bile acids (BA) play a pivotal role in cholesterol metabolism. Their blood concentration has also been proposed as new prognostic and diagnostic indicator of hepatobiliary, intestinal, and cardiovascular disease. Liquid chromatography tandem mass spectrometry (LC–MS/MS) currently represents the gold standard for analysis of BA profile in biological samples. We report here development and validation of a LC–MS/MS technique for simultaneously quantifying 15 BA species in serum samples. We also established a reference range for adult healthy subjects (n = 130) and performed a preliminary evaluation of in vitro and in vivo interference. The method displayed good linearity, with high regression coefficients (>0.99) over a range of 5 ng/mL (lower limit of quantification, LLOQ) and 5000 ng/mL for all analytes tested. The accuracies were between 85–115%. Both intra- and inter-assay imprecision was <10%. The recoveries ranged between 92–110%. Each of the tested BA species (assessed on three concentrations) were stable for 15 days at room temperature, 4 °C, and −20 °C. The in vitro study did not reveal any interference from triglycerides, bilirubin, or cell-free hemoglobin. The in vivo interference study showed that pools obtained from hyper-cholesterolemic patients and hyper-bilirubinemic patients due to post-hepatic jaundice for benign cholestasis, cholangiocarcinoma and pancreatic head tumors had clearly distinct patterns of BA concentrations compared with a pool obtained from samples of healthy subjects. In conclusion, this study proposes a new suitable candidate method for identification and quantitation of BA in biological samples and provides new insight into a number of variables that should be taken into account when investigating pathophysiological changes of BA in human diseases.

Highlights

  • Bile acids (BA) are amphipathic end products of cholesterol metabolism

  • Liquid chromatography–tandem mass spectrometry (LC–MS/MS) techniques are considered the gold standard for analysis of BA profile in both bile and serum samples [14]

  • Our proposed UHPLC–MS/MS (Ultra High Performance Liquid Chromatography- tandem mass spectrometry) technique would enable the quantification of 15 different bile acid species from 200 μL of spectrometry) technique would enable the quantification of 15 different bile acid species from 200 μL

Read more

Summary

Introduction

Bile acids (BA) are amphipathic end products of cholesterol metabolism. Primary BA Physiological and pathophysiological changes in circulating BA profiles have been associated with development of degenerative liver and intestinal diseases, chronic inflammation, gut barrier dysfunctions, cholestasis, and colon cancer [7,8]. Liquid chromatography–tandem mass spectrometry (LC–MS/MS) techniques are considered the gold standard for analysis of BA profile in both bile and serum samples [14]. These methods provide exceptional resolution, sensitivity and specificity. Simultaneous measurements of all BA into a single LC–MS/MS run is complex, and only few research groups worldwide have implemented this approach Another aspect that has been scarcely appreciated so far is the close dependence of BA levels on those of cholesterol, their precursor molecule. Reference ranges for single BA in a healthy adult population were established

Analytical Standards and Solvents
Sample Collection
Sample Preparation
Validation Procedures
Interference Study
In Vitro Study
In Vivo Study
Results
Optimal source-specific separation is shown inrun
Method Validation
Reference Ranges
Influence of hyper-cholesterolemia and hyperbilubinemia on BA
Discussion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call